Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE III: Gardasil in Mid-Adult Women
NCT00090220Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2004
- Primary completion
- May 2009
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, Cervical Cancer (CC), genital warts, vulvar cancer, vaginal cancer, sponsored by Merck & Co.. Started Jun 2004; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)genital wartsvulvar cancervaginal cancer
Beyond the preview
Go deeper on NCT00090220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090220.